32 results about "Orthostatic BP" patented technology

Novel controlled release pharmaceutical compositions for oral use containing midodrine and/or its active metabolite desglymidodrine. The novel compositions are designed to release midodrine and/or desglymidodrine after oral intake in a manner which enables absorption to take place in the gastrointestinal tract so that a relatively fast peak plasma concentration of the active metabolite desglymidodrine is obtained followed by a prolonged and relatively constant plasma concentration of desglymidodrine.

The novel compositions may be designed for administration once or twice daily, i.e. a therapeutically effective concentration of desglymidodrine is maintained for a period of at least 10-16 hours followed by a wash out period of about 8-12 hours in order to avoid the well-known midodrine related side effect with respect to supine hypertension. The therapeutically effective concentration of desglymidodrine is regarded as a plasma concentration of desglymidodrine of at least about 3 ng/ml. A composition is designed to release midodrine and/or desglymidodrine in at least the following consecutive steps: i) an initial relatively fast release of midodrine and/or desglymidodrine (in order to obtain a relatively fast onset of action), ii) a steady release or a slower release than in step 1 of midodrine and/or desglymidodrine (in order to maintain a plasma concentration of desglymidodrine which is prolonged and relatively constant), iii) a second rise in release of midodrine and/or desglymidodrine (in order to take advantage of absorption from the colon, i.e. such a second rise release is designed to take place when the composition (or the disintegrated parts of the composition) reaches the colon; normally this is regarded to take about 8 hours after oral intake, and iv) a decline in release rate corresponding to that essentially all midodrine and/or desglymidodrine have been released from the composition.

Also disclosed is a method for treating orthostatic hypotension and/or urinary incontinence, the method comprising administration to a patient in need thereof of an effective amount of midodrine and/or desglymidodrine in a composition according to the invention.

A non-invasive method and apparatus are provided for treating orthostatic hypotension and for reducing the effects caused there from. An increase in blood and fluid flow in the lower extremities is achieved by vibrating the lower body of the individual at a frequency in the range of 10-120 Hz. The apparatus includes a strap for being secured to a body part of the individual's lower extremities, e.g., the sole of one's foot, and a displacement sensor which senses any movement of the body part. The displacement sensor continuously sends signals to a processor of the apparatus which indicate whether there was any movement of the body part. If the displacement sensor did not sense any substantial movement of the body part for a predetermined period of time the processor sends a signal to a vibrating mechanism. The signal activates the vibrating mechanism causing vibration of the body part for increasing blood and fluid flow in the lower extremities. The vibrating mechanism causes vibration for a predetermined period of time.

Methods and compositions containing huperzine for direct delivery to central nervous system (CNS) tissue are used to alleviate pain and for the prevention and/or treatment of seizures and epilepsy. The invention is also directed to methods and compositions for using huperzine for the prevention and/or treatment of neuropathic pain and orthostatic hypotension.

The present invention provides methods and systems for reducing falls in patients that are recurrent fallers. Specifically, the compositions, systems, and methods can relate to Parkinson's disease patients, particularly such patients that are suffering from neurogenic orthostatic hypotension. The compositions, systems, and methods comprise the use of droxidopa, optionally in combination with a further active agent. Administration of droxidopa has been found to reduce the mean number of falls per patient per week, as well as provide improvements in the patient's Hoehn and Yahr rating scale score, which is indicative of improvements in postural stability, and provide improvements in the patient's Unified Parkinson's disease Rating Scale score, which is indicative of improvements in the severity of motor and/or non-motor symptoms of Parkinson's disease.

The invention discloses a pedestal pan ring capable of automatic lifting, which is characterized in that the pedestal pan ring can lift automatically through a lifting platform. The lifting power supply is provided by a motor, a driving gear of the output end of the motor is a worm, and a driven gear engaged with the driving gear is a turbine; an eccentric cylindrical sliding block is fixedly arranged at the side wall of the turbine and extends into a slideway of a swinging rod, the front end of the swinging rod is pinned on one side of a shaft arranged at the upper front end of a stand, and the swinging rod is also symmetrically arranged at the opposite side of the shaft and pinned on the other side of the shaft; back ends of two swinging rods are both provided with symmetrical slideways, two cylindrical sliding blocks are respectively arranged upside and downside two sides of the lifting platform integrated with the pedestal pan ring into a whole, and the lower cylindrical sliding block extends into the slideway; the upper and the lower cylindrical sliding blocks at two sides are arranged in the slideway at the back of the stand and perpendicular to the stand in a penetrating way; and an upper travel switch and a lower travel switch are arranged between the areas where the swinging rods move on the stand. After defecation, the motor is started and then the pedestal pan ring can be lifted slowly, therefore, the difficulties of pins and needles and standing up caused by compression of leg nervus vascularis are quickly relieved and orthostatic hypotension dizziness is prevented.

A method is provided for reducing the risk of sustaining a traumatic brain injury caused by a traumatic event that includes identifying a subject at risk of sustaining a traumatic brain injury, and then precisely increasing the partial pressure of carbon-dioxide (CO₂) in the blood of the subject (pCO₂). This method can be applied to raise the CO₂ and pCO₂ to improve orthostatic hypotension in conditions such as dysautonomias (like Positional Orthostatic Tachycardic Syndrome POTS) and to facilitate the drive to breathe in conditions like Central Sleep Apnea (CSA) and Sudden Infant Death Syndrome (SIDS). The pCO₂ of the person is increased by placing a breathing apparatus over the mouth of the person through which the person must breath, wherein the breathing apparatus includes an enlarged dead space volume in which expired CO₂ collects to be inhaled or re-breathed by the person on the next inhalation.

The present invention relates to an agent for preventing and/or treating diabetic neuropathy comprising a 2-[(substituted-inden-7-yloxy)methyl]morpholine of the formula (I) or a pharmaceutically acceptable salt thereof as an active ingredient. The invention is useful for providing an excellent agent for preventing and/or treating diabetic neuropathy, and particularly useful for providing an agent for preventing and/or treating diabetic motor neuropathy (such as muscle weakness disorder (such as muscle weakness disorder with inability to walk independently)), diabetic sensory neuropathy (such as paresthesia (such as vibration perception abnormality), allodynia, hypoesthesia (such as numbness of extremities or cold sensation), or pain), or diabetic autonomic neuropathy (such as stool abnormality (such as constipation or diarrhea), urination disorder, impotence, orthostatic hypotension, sudomotor dysfunction, abnormal heart rate variability, or delayed gastric emptying). Further, the invention is particularly useful for providing an agent for improving pathophysiology of diabetic neuropathy.

Methods of treating orthostatic hypotension are disclosed. The methods include administering to a subject in need thereof an effective amount of a beta 2 (β2) adrenoceptor antagonist, and in particular, the specific β2 adrenoceptor antagonist, 3-(isopropylamino)-1-[(7-methyl-4-indanyl)oxy]butan-2-ol.

The present invention provides a process for producing Droxidopa or a pharmaceutically acceptable salt thereof comprising a step of reacting threo-N-phthaloyl-3-(3,4-dihydroxyphenyl)-L-serine represented by the formula (1) with methylamine, whereby a process for producing threo-3-(3,4-dihydroxyphenyl)-L-serine (common name: Droxidopa), which is useful as an agent for treatment of peripheral orthostatic hypotension or an agent for treatment of Parkinson's disease, with high production efficiency and without requiring troublesome operations.